Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Telapristone Acetate Clear all
Completed Phase 2 Interventional Results available

Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003

NCT00958334
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex®
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Phoenix, Arizona • San Diego, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Crossover Study of the Safety and PK Properties of Proellex®

NCT00749879
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 34 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of Two Formulations of Proellex for Oral Administration

NCT02141061
View directory record Official record
Conditions
Healthy
Interventions
Telapristone Acetate, Proellex 12 mg Formulation A, Telapristone Acetate, Proellex 12 mg Formulation B
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Oct 20, 2026, 6:16 PM EDT
Withdrawn Phase 2 Interventional

Open-Label Extension Study to ZPE-202

NCT01961908
View directory record Official record
Conditions
Endometriosis
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Little Rock, Arkansas • Clearwater, Florida • Margate, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2014 · Synced Oct 20, 2026, 6:16 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids

NCT00853567
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex, placebo
Drug · Other
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
17
States / cities
Anaheim, California • Los Angeles, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Proellex Pharmacokinetics Bridging Study

NCT01067807
View directory record Official record
Conditions
Healthy
Interventions
25 mg Proellex, 50 mg Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Oct 20, 2026, 6:16 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis

NCT00556075
View directory record Official record
Conditions
Endometriosis
Interventions
Proellex 25 mg, Placebo, Proellex 50 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2014 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids

NCT02323646
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Placebo, Telapristone Acetate
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Fort Lauderdale, Florida • Sandy Springs, Georgia • Metairie, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 20, 2026, 6:16 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids

NCT00735553
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of Two Formulations of Proellex for Vaginal Administration

NCT01962805
View directory record Official record
Conditions
Comparison of 2 Different Formulations of 12 mg Proellex Vaginal Capsules
Interventions
Proellex Formulation A, Proellex Formulation B
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 20, 2026, 6:16 PM EDT
Terminated Phase 2 Interventional Results available

An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

NCT02811159
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Telapristone acetate
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Fort Lauderdale, Florida • Atlanta, Georgia • Sandy Springs, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional Results available

Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy

NCT02314156
View directory record Official record
Conditions
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma In Situ, Lobular Breast Carcinoma In Situ, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
Interventions
Telapristone Acetate, Placebo, Laboratory Biomarker Analysis, Questionnaire Administration
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
3
States / cities
West Hollywood, California • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids

NCT01451424
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Miami Gardens, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 20, 2026, 6:16 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females

NCT00787618
View directory record Official record
Conditions
Renal Impairment
Interventions
50 mg Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2014 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis

NCT01728454
View directory record Official record
Conditions
Endometriosis
Interventions
Placebo, Telapristone acetate
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
Tucson, Arizona • Little Rock, Arkansas • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Determination of the Lowest, Safe and Effective Dose of Proellex

NCT01187043
View directory record Official record
Conditions
Amenorrhea
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Oct 20, 2026, 6:16 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids

NCT01069120
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
4
States / cities
Boynton Beach, Florida • Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional Results available

A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

NCT02301897
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Telapristone Acetate, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy Females

NCT00881062
View directory record Official record
Conditions
ABSORPTION, METABOLISM, EXCRETION
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety and Pharmacokinetic Study of Proellex®

NCT00619385
View directory record Official record
Conditions
Healthy
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 34 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 20, 2026, 6:16 PM EDT
Withdrawn Phase 3 Interventional

Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms

NCT00874302
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
San Diego, California • Sarasota, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional

Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

NCT00882258
View directory record Official record
Conditions
Uterine Fibroids
Interventions
12.5 mg Proellex, 25 mg Proellex, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults

NCT00741273
View directory record Official record
Conditions
Impaired Liver Function
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 62 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Oct 20, 2026, 6:16 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Menses Induction in Women Administered Proellex

NCT00881608
View directory record Official record
Conditions
Amenorrhea
Interventions
Placebo, Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2014 · Synced Oct 20, 2026, 6:16 PM EDT